中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [304]
采集方式
OAI收割 [304]
内容类型
期刊论文 [298]
会议论文 [6]
发表日期
2024 [8]
2023 [33]
2022 [17]
2021 [23]
2020 [11]
2019 [28]
更多
学科主题
Chemistry [5]
Pharmacolo... [5]
Biochemist... [2]
Endocrinol... [1]
Neuroscien... [1]
筛选
浏览/检索结果:
共304条,第1-10条
帮助
限定条件
专题:上海药物研究所
第一署名单位
第一作者单位
通讯作者单位
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
提交时间升序
提交时间降序
发表日期升序
发表日期降序
题名升序
题名降序
作者升序
作者降序
Pharmacological inhibition of Kir4.1 evokes rapid-onset antidepressant responses
期刊论文
OAI收割
NATURE CHEMICAL BIOLOGY, 2024, 页码: 29
作者:
Zhou, Xiaoyu
;
Zhao, Cheng
;
Xu, Haiyan
;
Xu, Yixiang
;
Zhan, Li
  |  
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2024/03/25
Novel imidazo[1,2,4] triazole derivatives: Synthesis, fluorescence, bioactivity for SHP1
期刊论文
OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 265, 页码: 15
作者:
Yan, Xue
;
Zhang, Chun
;
Gao, Li-Xin
;
Liu, Min -Min
;
Yang, Yu-Ting
  |  
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2024/02/27
Imidazo[124] triazole derivatives
Fluorescence property
SHP1
Bioactivity
Cellular imaging
An LQT2-related mutation in the voltage-sensing domain is involved in switching the gating polarity of hERG
期刊论文
OAI收割
BMC BIOLOGY, 2024, 卷号: 22, 期号: 1, 页码: 14
作者:
Liu, Zhipei
;
Wang, Feng
;
Yuan, Hui
;
Tian, Fuyun
;
Yang, Chuanyan
  |  
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2024/03/13
hERG
K525N
Gating Polarity
Voltage-Sensing Domain
LQT2
Blocking tumor-platelet crosstalk to prevent tumor metastasis via reprograming glycolysis using biomimetic membrane-hybridized liposomes
期刊论文
OAI收割
JOURNAL OF CONTROLLED RELEASE, 2024, 卷号: 366, 页码: 328-341
作者:
Zhu, Jie
;
Wang, Rui
;
Yang, Chenxiao
;
Shao, Xinyue
;
Zhang, Yi
  |  
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2024/03/06
Platelet
Circulating tumor cells (CTCs)
Glycolysis
Metastasis
Hybrid-membrane liposome
Quercetin
Shikonin
Development and Validation of an ADA-Tolerant Assay for Quantification of an Exatecan-Based ADC in Monkey Plasma
期刊论文
OAI收割
MOLECULES, 2024, 卷号: 29, 期号: 3, 页码: 14
作者:
Tao, Yimin
;
Lu, Wei
;
Gao, Jinli
;
Yang, Shuangshuang
;
Ruan, Chaoyi
  |  
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2024/03/13
antibody-drug conjugate (ADC)
bioanalysis
anti-drug antibody (ADA)
ligand binding assay (LBA)
ADA-tolerant assay
Xuanbai Chengqi Decoction alleviates acute lung injury by inhibiting NLRP3 inflammasome
期刊论文
OAI收割
JOURNAL OF ETHNOPHARMACOLOGY, 2024, 卷号: 319, 页码: 13
作者:
Wang, Shun
;
Lin, Feifei
;
Zhang, Chengxi
;
Gao, Dan
;
Qi, Zhuocao
  |  
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2023/12/08
Xuanbai Chengqi Decoction
Acute lung injury
NLRP3 inflammasome
Pyroptosis
Metabolic regulation of homologous recombination repair by MRE11 lactylation
期刊论文
OAI收割
CELL, 2024, 卷号: 187, 期号: 2, 页码: 40
作者:
Chen, Yuping
;
Wu, Jinhuan
;
Zhai, Linhui
;
Zhang, Tingting
;
Yin, Hui
  |  
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2024/04/09
Editorial: Advances in novel drugs and targets for hepatic and gastrointestinal diseases
期刊论文
OAI收割
FRONTIERS IN PHARMACOLOGY, 2024, 卷号: 15, 页码: 4
作者:
Ngowi, Ebenezeri Erasto
;
Gao, Yong
;
Yang, Xiaoying
;
Qiao, Aijun
  |  
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2024/02/27
novel drugs
target
liver diseases
gastrointestinal diseases
molecular mechanism
Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
期刊论文
OAI收割
ACTA PHARMACOLOGICA SINICA, 2023, 页码: 12
作者:
Lin, Ting-ting
;
Xiong, Wei
;
Chen, Gui-hua
;
He, Yang
;
Long, Li
  |  
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2024/01/26
osimertinib resistance
targeted drug delivery
liposomes
panobinostat
tumor-associated macrophage
combination therapy
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation
期刊论文
OAI收割
ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2023, 卷号: 55, 期号: 12, 页码: 1884-1891
作者:
Jin, Shuhan
;
Li, Bo
;
Zhang, Bibo
;
Gao, Xuejie
;
Jia, Xinyan
  |  
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2024/02/27
dihydrocelastrol
multiple myeloma
JAK2/STAT3
PSMB5
bortezomib resistance